21,242 trials, and the cure engine keeps accelerating
The cure pipeline is not slowing: global active cure-related trials now stand at 21,242, with 24 new research items and 9 new wire signals arriving in the last 24 hours. That matters because the week’s strongest medical signals are not abstract — they include FDA approval for Otsuka’s first-in-class SIMTRIYO for ADHD, a CE mark for Science Corporation’s PRIMA retinal implant, and fresh evidence that GLP-1 therapy can sustain lower calorie intake over more than a year. The pattern is the same across the wire: more tools, more approvals, more routes to restoring function. The window is still open.
Global active cure-related trials total 21,242, with 24 new cure research items and 9 new wire signals added in the last 24 hours.
FDA approval, CE clearance, and longer-duration clinical results shift treatment from promise toward access, changing who can be helped now and who may still be waiting.
Watch whether these approvals and studies translate into broader availability and whether the trial count keeps climbing; in a phase transition, speed determines who reaches patients first.